N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis (NACAH)
Primary Purpose
Alcoholic Hepatitis, Infection
Status
Recruiting
Phase
Phase 3
Locations
United Kingdom
Study Type
Interventional
Intervention
N-acetyl cysteine (NAC)
Sponsored by
About this trial
This is an interventional treatment trial for Alcoholic Hepatitis
Eligibility Criteria
Inclusion Criteria:
- Aged 18 years or older
Clinical alcoholic hepatitis:
- Serum bilirubin >80umol/L
- History of alcohol excess (>80g/day male, >60g/day female)
- Less than 4 weeks since admission to hospital
- Maddrey's discriminant function (DF) >32
- Informed consent
Exclusion Criteria:
- Alcohol abstinence of >6 weeks prior to randomisation
- Duration of jaundice >3 months
Other causes of liver disease including:
- Evidence of viral hepatitis (hepatitis B or C)
- Biliary obstruction
- Hepatocellular carcinoma
- Evidence of current malignancy (except non-melanotic skin cancer)
- Previous entry into the study
- Patients with known hypersensitivity or previous reactions to NAC
- Pregnant or lactating women
Sites / Locations
- St Mary's Hospital, Imperial CollegeRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
prednisolone+NAC
prednisolone
Arm Description
40mg prednisolone once a day for 28 days and 30 minutes of intravenous NAC at 150mg/kg in 250ml 5% dextrose solution followed by 4 hours of intravenous NAC at 50mg/kg in 500ml 5% dextrose solution, followed by 16 hours of intravenous NAC at 100 mg/kg in 1000ml 5% dextrose solution, followed by 4 days of intravenous NAC at 100mg/kg/day in 1000ml 5% dextrose solution
40mg prednisolone for 28 days
Outcomes
Primary Outcome Measures
Improvement in monocyte oxidative burst
Improvement in ex vivo monocyte oxidative burst
Secondary Outcome Measures
Proportion of patients infected
Infection will be defined in two ways: i. by new/change in intravenous antibiotic prescription and ii. published clinical and microbiological criteria for infection in the setting of liver disease
Proportion of patients infected
Infection will be defined in two ways: i. by new/change in intravenous antibiotic prescription and ii. published clinical and microbiological criteria for infection in the setting of liver disease
Death
Death
Full Information
NCT ID
NCT03069300
First Posted
February 28, 2017
Last Updated
November 8, 2021
Sponsor
Imperial College London
1. Study Identification
Unique Protocol Identification Number
NCT03069300
Brief Title
N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis
Acronym
NACAH
Official Title
The Mechanism of Action of N-acetylcysteine for Reducing the Risk of Infection in Alcoholic Hepatitis
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2015 (Actual)
Primary Completion Date
April 1, 2022 (Anticipated)
Study Completion Date
June 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Recent data have suggested that monocyte oxidative burst defect is associated with the development of infection in patients with severe alcoholic hepatitis. One report found reduced 28 day mortality in patients treated with N-acetylcysteine combined with prednisolone when compared to prednisolone alone. The current study seeks to reveal whether the mechanism by which NAC reduces susceptibility to infection is through improvement of phagocyte oxidative burst.
Detailed Description
Randomised controlled trial, open label.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcoholic Hepatitis, Infection
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
randomized controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
42 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
prednisolone+NAC
Arm Type
Experimental
Arm Description
40mg prednisolone once a day for 28 days and 30 minutes of intravenous NAC at 150mg/kg in 250ml 5% dextrose solution followed by 4 hours of intravenous NAC at 50mg/kg in 500ml 5% dextrose solution, followed by 16 hours of intravenous NAC at 100 mg/kg in 1000ml 5% dextrose solution, followed by 4 days of intravenous NAC at 100mg/kg/day in 1000ml 5% dextrose solution
Arm Title
prednisolone
Arm Type
No Intervention
Arm Description
40mg prednisolone for 28 days
Intervention Type
Drug
Intervention Name(s)
N-acetyl cysteine (NAC)
Other Intervention Name(s)
NAC
Primary Outcome Measure Information:
Title
Improvement in monocyte oxidative burst
Time Frame
24 hours
Title
Improvement in ex vivo monocyte oxidative burst
Time Frame
5 days
Secondary Outcome Measure Information:
Title
Proportion of patients infected
Description
Infection will be defined in two ways: i. by new/change in intravenous antibiotic prescription and ii. published clinical and microbiological criteria for infection in the setting of liver disease
Time Frame
28 days
Title
Proportion of patients infected
Description
Infection will be defined in two ways: i. by new/change in intravenous antibiotic prescription and ii. published clinical and microbiological criteria for infection in the setting of liver disease
Time Frame
90 days
Title
Death
Time Frame
28 days
Title
Death
Time Frame
90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Aged 18 years or older
Clinical alcoholic hepatitis:
Serum bilirubin >80umol/L
History of alcohol excess (>80g/day male, >60g/day female)
Less than 4 weeks since admission to hospital
Maddrey's discriminant function (DF) >32
Informed consent
Exclusion Criteria:
Alcohol abstinence of >6 weeks prior to randomisation
Duration of jaundice >3 months
Other causes of liver disease including:
Evidence of viral hepatitis (hepatitis B or C)
Biliary obstruction
Hepatocellular carcinoma
Evidence of current malignancy (except non-melanotic skin cancer)
Previous entry into the study
Patients with known hypersensitivity or previous reactions to NAC
Pregnant or lactating women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nikhil Vergis, PhD
Email
nvergis@ic.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Mark Thursz, MD
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Thursz, MD
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
St Mary's Hospital, Imperial College
City
London
ZIP/Postal Code
W2 1NY
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nikhil Vergis, PhD
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
contact investigators
Citations:
PubMed Identifier
22070475
Citation
Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL; AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011 Nov 10;365(19):1781-9. doi: 10.1056/NEJMoa1101214.
Results Reference
background
PubMed Identifier
26860769
Citation
Vergis N, Khamri W, Beale K, Sadiq F, Aletrari MO, Moore C, Atkinson SR, Bernsmeier C, Possamai LA, Petts G, Ryan JM, Abeles RD, James S, Foxton M, Hogan B, Foster GR, O'Brien AJ, Ma Y, Shawcross DL, Wendon JA, Antoniades CG, Thursz MR. Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. Gut. 2017 Mar;66(3):519-529. doi: 10.1136/gutjnl-2015-310378. Epub 2016 Feb 9.
Results Reference
result
Learn more about this trial
N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis
We'll reach out to this number within 24 hrs